{"id":2277,"date":"2026-07-29T09:15:00","date_gmt":"2026-07-29T13:15:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=2277"},"modified":"2026-07-29T20:12:20","modified_gmt":"2026-07-30T00:12:20","slug":"fda-panel-votes-against-deramiocel","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=2277","title":{"rendered":"FDA Panel Votes Against Deramiocel"},"content":{"rendered":"

\"\"<\/p>\n

Company<\/strong><\/p>\n

Capricor Therapeutics<\/p>\n

Event Type<\/strong><\/p>\n

Regulatory (Advisory Committee Vote)<\/p>\n

Modality<\/strong><\/p>\n

Allogeneic cardiosphere-derived cell therapy<\/p>\n

Asset<\/strong><\/p>\n

Deramiocel (BLA 125842)<\/p>\n

Target<\/strong><\/p>\n

Inflammation, fibrosis, and tissue repair via paracrine signaling<\/p>\n

Disease Area<\/strong><\/p>\n

Cardiomyopathy associated with Duchenne muscular dystrophy<\/p>\n

Summary<\/h4>\n

FDA’s Cellular, Tissue, and Gene Therapies Advisory Committee voted 9-3 that the evidence did not support approval of deramiocel for cardiomyopathy associated with Duchenne muscular dystrophy. The vote is nonbinding, but it materially increases regulatory risk ahead of the August 22 PDUFA date. The central issue was not an acute safety signal; it was whether Capricor’s analyses and total evidence constitute persuasive, reliable proof of effectiveness after the Phase 3 study’s prespecified-analysis controversy.<\/p>\n

The committee reviewed BLA 125842 for deramiocel, an allogeneic cardiosphere-derived cell therapy. After discussion of the HOPE-2, open-label extension, and HOPE-3 evidence, members voted 9-3 against the proposition that the available data support approval.<\/p>\n

Reviewers focused on changes and disagreements involving the statistical analysis plan, the interpretation of the upper-limb endpoint, and failure on a key prespecified cardiac measure. Capricor argued that its final analysis plan was completed before unblinding and that the totality of evidence supports clinically meaningful skeletal and cardiac benefit.<\/p>\n

The advisory recommendation is not an FDA decision. Deramiocel remains investigational, and FDA is expected to act by August 22, 2026.<\/p>\n

Scientific, clinical, and regulatory interpretation<\/h4>\n

The negative vote reflects evidence reliability more than mechanism. Deramiocel is intended to modulate inflammation, fibrosis, and tissue repair through paracrine signaling from allogeneic cardiosphere-derived cells. A plausible mechanism cannot substitute for prospectively defined and reproducible clinical benefit.<\/p>\n

Capricor has emphasized a reported 54% slowing of decline on the Performance of the Upper Limb measure. However, post hoc or contested analytic choices reduce confidence even when the numerical effect appears clinically relevant. Failure on a key cardiac endpoint is particularly important because the proposed indication centers on DMD cardiomyopathy.<\/p>\n

Strategic and competitive implications<\/h4>\n

A 9-3 vote substantially raises the probability of a complete response letter, request for additional controlled evidence, narrower label, or other restrictive outcome. FDA can diverge from the committee, but doing so would require the agency to resolve the same evidentiary concerns articulated publicly.<\/p>\n

The broader implication is a high bar for cell therapies supported by complex or amended statistical packages. Sponsors should expect intense scrutiny of prespecification, multiplicity control, endpoint hierarchy, missing data, and consistency across functional and organ-specific outcomes.<\/p>\n

Alternative interpretations and validation gate<\/h4>\n

The negative interpretation is that the efficacy package is not sufficiently reliable for approval. The counterargument is that a rare, progressive disease with limited options may justify weighing totality, external consistency, and clinically meaningful upper-limb preservation more heavily.<\/p>\n

The signal would improve only if FDA explains why the totality of evidence overcomes the committee’s concerns or if Capricor produces prospectively specified confirmatory data. It would worsen with a complete response letter requiring another controlled trial or findings that further undermine the analytic chain.<\/p>\n

Signal Extraction<\/h4>\n
    \n
  • New regulatory event: advisory committee voted 9-3 against approval support.<\/li>\n
  • Direction: negative\/mixed; approval risk rises, but the final decision is pending.<\/li>\n
  • Primary concern: evidentiary and statistical reliability rather than a newly identified acute safety issue.<\/li>\n
  • Status: deramiocel remains investigational.<\/li>\n
  • Next catalyst: FDA action by August 22, 2026.<\/li>\n<\/ul>\n

    InSilens Take<\/h4>\n

    This is a high-importance negative regulatory signal. The correct wording is not that FDA rejected deramiocel; FDA has not issued its decision. The committee’s vote nevertheless changes the base case because the dispute now concerns whether the application meets the effectiveness standard, not a remediable administrative detail.<\/p>\n

    Company and Product Background<\/h4>\n

    Duchenne muscular dystrophy is caused by loss of dystrophin and leads to progressive skeletal, respiratory, and cardiac muscle degeneration. Cardiomyopathy is a major cause of morbidity and mortality.<\/p>\n

    Deramiocel consists of allogeneic cardiosphere-derived cells intended to exert immunomodulatory, antifibrotic, and regenerative paracrine effects. It is being reviewed under BLA 125842.<\/p>\n

    Signal Assessment<\/h4>\n

    Signal Importance is rated 5\/5 with a Negative\/mixed direction. Confidence in the underlying facts is High; confidence in the forward-looking interpretation is Medium-High. The result would be falsified by an FDA approval that explicitly resolves the statistical and endpoint concerns.<\/p>\n","protected":false},"excerpt":{"rendered":"

    FDA’s Cellular, Tissue, and Gene Therapies Advisory Committee voted 9-3 that the evidence did not support approval of deramiocel for cardiomyopathy associated with Duchenne muscular dystrophy. The vote is nonbinding, but it materially increases…<\/p>\n","protected":false},"author":1,"featured_media":2294,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1,11,3],"tags":[210,84],"class_list":["post-2277","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-all-categories","category-clinical","category-therapeutic-indication","tag-capricor-therapeutics","tag-duchenne-muscular-dystrophy"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2277","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2277"}],"version-history":[{"count":2,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2277\/revisions"}],"predecessor-version":[{"id":2297,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2277\/revisions\/2297"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/2294"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2277"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2277"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2277"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}